130 related articles for article (PubMed ID: 18786779)
21. Recent developments in chemoradiotherapy for locally advanced cancer of the cervix.
Kim RY; Alvarez RD
Oncology (Williston Park); 2000 Sep; 14(9):1327-31, 1335; discussion 1336-8. PubMed ID: 11033830
[TBL] [Abstract][Full Text] [Related]
22. Role of systemic chemotherapy in metastatic cervical cancer.
Hogg R; Friedlander M
Expert Rev Anticancer Ther; 2003 Apr; 3(2):234-40. PubMed ID: 12722882
[TBL] [Abstract][Full Text] [Related]
23. Toxicity after cervical cancer treatment using radiotherapy and chemotherapy.
Jones B
Clin Oncol (R Coll Radiol); 2009 Feb; 21(1):56-63. PubMed ID: 19046625
[TBL] [Abstract][Full Text] [Related]
24. Normal tissue complication probability: does simultaneous integrated boost intensity-modulated radiotherapy score over other techniques in treatment of prostate adenocarcinoma.
Basu KS; Bahl A; Subramani V; Sharma DN; Rath GK; Julka PK
J Cancer Res Ther; 2009; 5(2):78-84. PubMed ID: 19542662
[TBL] [Abstract][Full Text] [Related]
25. Fractionated grid therapy in treating cervical cancers: conventional fractionation or hypofractionation?
Zhang H; Wang JZ; Mayr N; Kong X; Yuan J; Gupta N; Lo S; Grecula J; Montebello J; Martin D; Yuh W
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):280-8. PubMed ID: 17967516
[TBL] [Abstract][Full Text] [Related]
26. Further radiobiologic modeling of palliative radiotherapy: use of virtual trials.
Jones B; Dale RG
Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):221-9. PubMed ID: 17707276
[TBL] [Abstract][Full Text] [Related]
27. Retrospective analysis: concurrent chemoradiotherapy and adjuvant chemotherapy for T2N0 glottic squamous cell carcinoma.
Nonoshita T; Shioyama Y; Kunitake N; Nakamura K; Nomoto S; Ohga S; Toriya Y; Ono M; Honda H
Fukuoka Igaku Zasshi; 2009 Jan; 100(1):26-31. PubMed ID: 19378773
[TBL] [Abstract][Full Text] [Related]
28. Factors associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer.
Watkins JM; Wahlquist AE; Shirai K; Garrett-Mayer E; Aguero EG; Fortney JA; Sherman CA; Sharma AK
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1108-13. PubMed ID: 19084345
[TBL] [Abstract][Full Text] [Related]
29. Correction to Kasibhatla et al. How much radiation is the chemotherapy worth in advanced head and neck cancer? (Int j radiat oncol biol phys 2007;68:1491-1495).
Fowler JF
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):326-9. PubMed ID: 18474309
[TBL] [Abstract][Full Text] [Related]
30. Clinical impact of computed tomography-based image-guided brachytherapy for cervix cancer using the tandem-ring applicator - the Addenbrooke's experience.
Tan LT; Coles CE; Hart C; Tait E
Clin Oncol (R Coll Radiol); 2009 Apr; 21(3):175-82. PubMed ID: 19101130
[TBL] [Abstract][Full Text] [Related]
31. Maximum tolerated dose and early response - results of a phase I trial of paclitaxel and cisplatin with radiation therapy in carcinoma of the cervix.
Prasad E; Viswanathan PN; Rangad VF; Pavamani S; Ram TS
Clin Oncol (R Coll Radiol); 2009 Aug; 21(6):488-93. PubMed ID: 19386478
[TBL] [Abstract][Full Text] [Related]
32. [Chemoradiotherapy: innovation in treatment of high-risk cervical cancer].
Piura B; Meirovitz M
Harefuah; 2000 Mar; 138(6):482-7. PubMed ID: 10883165
[No Abstract] [Full Text] [Related]
33. Biologically-equivalent dose and long-term survival time in radiation treatments.
Zaider M; Hanin L
Phys Med Biol; 2007 Oct; 52(20):6355-62. PubMed ID: 17921589
[TBL] [Abstract][Full Text] [Related]
34. [Chemotherapy improves the treatment results of cervical cancer].
Jalkanen J
Duodecim; 1999; 115(22):2417-8. PubMed ID: 11973965
[No Abstract] [Full Text] [Related]
35. Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis.
Chan SH; Ng WT; Kam KL; Lee MC; Choi CW; Yau TK; Lee AW; Chow SK
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1335-42. PubMed ID: 18922648
[TBL] [Abstract][Full Text] [Related]
36. A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study.
Cho KH; Ahn SJ; Pyo HR; Kim KS; Kim YC; Moon SH; Han JY; Kim HT; Koom WS; Lee JS
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1397-404. PubMed ID: 19117690
[TBL] [Abstract][Full Text] [Related]
37. Extended-field radiation therapy with whole pelvis radiotherapy and cisplatin chemosensitization in the treatment of IB2-IIIB cervical carcinoma: a retrospective review.
Ring KL; Young JL; Dunlap NE; Andersen WA; Schneider BF
Am J Obstet Gynecol; 2009 Jul; 201(1):109.e1-6. PubMed ID: 19398095
[TBL] [Abstract][Full Text] [Related]
38. Correlation of a hypoxia based tumor control model with observed local control rates in nasopharyngeal carcinoma treated with chemoradiotherapy.
Avanzo M; Stancanello J; Franchin G; Sartor G; Jena R; Drigo A; Dassie A; Gigante M; Capra E
Med Phys; 2010 Apr; 37(4):1533-44. PubMed ID: 20443474
[TBL] [Abstract][Full Text] [Related]
39. Comparison between the ideal reference dose level and the actual reference dose level from clinical 3D radiotherapy treatment plans.
Bufacchi A; Arcangeli G; delle Canne S; Malatesta T; Capparella R; Fragomeni R; Marmiroli L; Begnozzi L
Radiother Oncol; 2009 Jul; 92(1):68-75. PubMed ID: 19328571
[TBL] [Abstract][Full Text] [Related]
40. Chemoradiotherapy for cervical cancer: what next?
Eifel PJ
J Clin Oncol; 2005 Nov; 23(33):8277-9. PubMed ID: 16230671
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
